Driving Biopharmaceutical Advancements of Plant-Derived Cannabinoid-Based Products
At the MaRS Discovery District Toronto
Who We Are
Avicanna is a Canadian commercial-stage biopharmaceutical company
Leading in cannabinoid research, development, and evidence-based products for the global consumer medical and pharmaceutical segments.
Corporate Overview
Global commercialization strategy with diversified & high margin income streams across 12+ countries.
Comprehensive commercial portfolio
Consumer, medical cannabis and cannabinoid supply chain
Multinational sales with international footprint
USA, Canada, Europe and LATAM
Revenue generation and scale up phase
3 consecutive Q-Q growth of minimum 30%
Proven scientific platform, including R&D, pre-clinical and clinical infrastructure in Canada
Cannabinoid drug development pipeline
30+ advanced commercial SKUs + pharmaceutical pipeline
World-renowned collaborations
with leading Canadian academic and clinical institutions
JLABS @ Toronto, Johnson & Johnson Innovation Centre
R&D headquarters in the MaRS Discovery District
Established and environmentally sustainable low-cost vertical integration in Colombia
Two Colombian majority-owned subsidiaries
cultivation footprint of 480,000 sq feet with industrial extraction capacity
World-renowned collaborations
with leading Canadian academic and clinical institutions
Organic and sustainable cultivation
ranked highest amongst global cannabis companies in a corporate sustainability assessment – issued by S&P Global in 2020
Our Portfolio
Including cosmetics, medical cannabis, pharmaceuticals in addition to its raw material business unit across international markets
Commercial Stage
Medical Cannabis and Wellness Products
Commercial Stage
CBD Dermacosmetics Consumer Retail Products
In Development and Registration Stage
Pharmaceutical Pipeline
Commercial Stage
Cannabinoid API & Seeds
Industry Leading Scientific Platform
Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products
Established Research & Development Platform
Setting the Standard in the Cannabinoid Industry with Advanced and Evidence Based Product
R&D headquarters at JLABS @ Toronto, Johnson & Johnson Innovation Centre in the MaRS Discovery District Drug development pipeline, including sustained release tablets, transdermal patches and nano participle formulations
30+
Commercial stage proprietary products
10+
Scientists
7+
Canadian Government research grants awarded since 2020
8+
Pending Patents
4+
Health Canada cannabis R&D licenses issued to Avicanna and its academic collaborators
World-Class Collaborations
R&D and Clinical Partnerships Over the Past 4 Years
World-Class Collaborations
R&D and clinical collaborations with world-class academic and medical institutes since 2016
MaRS Discovery
District
University Health
Network
Hospital of
Sick Children
University of
Guelph
JLABS @ Toronto
University of
Toronto
Sunnybrook Health
Science Centre
Thompson Rivers
University
Clinical Development
Setting the Standard in the Cannabinoid Industry on Advanced and Evidence-Based Products
08.08.2021
Products & Pipeline
Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products
